VISEN PHARMA-B Repurchases 10,200 Shares, Lifts Treasury Stock to 43,400 Units

Bulletin Express05-26

VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate.

On-market repurchase details • Volume: 10,200 ordinary shares • Price range: HKD 22.66–23.48 per share • Volume-weighted average price (per Section I): HKD 22.86 • Aggregate consideration: HKD 0.23 million

Capital structure after the transaction • Issued shares (excluding treasury shares) decreased to 113.88 million. • Treasury shares rose to 43,400, leaving total issued shares unchanged at 113.93 million. • The shares repurchased represent approximately 0.009 % of the company’s issued share capital prior to the transaction.

Repurchase mandate status • Mandate granted on 27 June 2025 authorises buybacks of up to 11.39 million shares. • Cumulative repurchases under this mandate now total 43,400 shares, equivalent to 0.038 % of issued shares at the mandate date. • A 30-day moratorium on new share issues or treasury share disposals runs until 25 June 2026.

Board confirmation The company affirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152263566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152263566","market":"hk","top_or_hot":-1,"title":"VISEN PHARMA-B Repurchases 10,200 Shares, Lifts Treasury Stock to 43,400 Units","media":"Bulletin Express","content":"<p>VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate.</p>\n<p>On-market repurchase details  \n• Volume: 10,200 ordinary shares  \n• Price range: HKD 22.66–23.48 per share  \n• Volume-weighted average price (per Section I): HKD 22.86  \n• Aggregate consideration: HKD 0.23 million</p>\n<p>Capital structure after the transaction  \n• Issued shares (excluding treasury shares) decreased to 113.88 million.  \n• Treasury shares rose to 43,400, leaving total issued shares unchanged at 113.93 million.  \n• The shares repurchased represent approximately 0.009 % of the company’s issued share capital prior to the transaction.</p>\n<p>Repurchase mandate status  \n• Mandate granted on 27 June 2025 authorises buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now total 43,400 shares, equivalent to 0.038 % of issued shares at the mandate date.  \n• A 30-day moratorium on new share issues or treasury share disposals runs until 25 June 2026.</p>\n<p>Board confirmation  \nThe company affirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Repurchases 10,200 Shares, Lifts Treasury Stock to 43,400 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Repurchases 10,200 Shares, Lifts Treasury Stock to 43,400 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-26 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate.</p>\n<p>On-market repurchase details  \n• Volume: 10,200 ordinary shares  \n• Price range: HKD 22.66–23.48 per share  \n• Volume-weighted average price (per Section I): HKD 22.86  \n• Aggregate consideration: HKD 0.23 million</p>\n<p>Capital structure after the transaction  \n• Issued shares (excluding treasury shares) decreased to 113.88 million.  \n• Treasury shares rose to 43,400, leaving total issued shares unchanged at 113.93 million.  \n• The shares repurchased represent approximately 0.009 % of the company’s issued share capital prior to the transaction.</p>\n<p>Repurchase mandate status  \n• Mandate granted on 27 June 2025 authorises buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now total 43,400 shares, equivalent to 0.038 % of issued shares at the mandate date.  \n• A 30-day moratorium on new share issues or treasury share disposals runs until 25 June 2026.</p>\n<p>Board confirmation  \nThe company affirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1152263566","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152263566","pubTimestamp":1779793371,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate. On-market repurchase details   • Volume: 10,200 ordinary shares   •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN PHARMA-B回购10,200股，库存股增至43,400股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate.\nOn-market repurchase details  \n• Volume: 10,200 ordinary shares  \n• Price range: HKD 22.66–23.48 per share  \n• Volume-weighted average price (per Section I): HKD 22.86  \n• Aggregate consideration: HKD 0.23 million\nCapital structure after the transaction  \n• Issued shares (excluding treasury shares) decreased to 113.88 million.  \n• Treasury shares rose to 43,400, leaving total issued shares unchanged at 113.93 million.  \n• The shares repurchased represent approximately 0.009 % of the company’s issued share capital prior to the transaction.\nRepurchase mandate status  \n• Mandate granted on 27 June 2025 authorises buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now total 43,400 shares, equivalent to 0.038 % of issued shares at the mandate date.  \n• A 30-day moratorium on new share issues or treasury share disposals runs until 25 June 2026.\nBoard confirmation  \nThe company affirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152263566","isCrawlerRequest":true}